[en] Background: Current treatment options for stage III non-small cell lung cancer (NSCLC) consist of different combinations of chemotherapy, surgery, radiotherapy and immunotherapy. Treatment choices are highly individual decisions, in which adverse events (AEs) are relevant for decision-making. This study aims to analyse reporting of AEs in prospective stage III NSCLC trials, focussing on trials including radiotherapy and/or surgery.
Methods: PubMed was searched for prospective studies dealing with stage III NSCLC from January 1987 to April 2019. Meta-analyses were screened as a positive control. Pearson’s Chi-squared test and smooth kernel distribution were used to estimate distributions. Data was resampled using bootstrapping.
Results: Out of 1193 initially identified studies, 119 met the inclusion criteria. Of these, 31 had a surgical procedure in any study arm. Grade 3 and 4 AEs were reported in 94.12% and 92.44% of the included studies, respectively. Reporting of grade 5 AEs was provided in 87.39% of cases. Grade 1 and 2 AEs were less commonly reported at 53.78% and 63.03%, respectively. One study did not mention any AEs. Of the 31 treatment arms including any form of surgery, AEs were not reported in 10. Overall, 231 different AE items were reported, only 18 of them were included in at least 20% of the analysed studies.
Conclusion: Overall, AE reporting in stage III NSCLC was inconsistent and inhomogeneous. Studies including surgical study arms often reported only treatment-related deaths in regards of surgical AEs. Underreporting of AEs prohibits the extraction of patient-relevant information for decision-making and represents a suboptimal use of invested resources.
Disciplines :
Surgery
Author, co-author :
Iseli, Thomas; Kantonsspital St Gallen, St Gallen, Switzerland > Dept of Radiation Oncology
Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11: 39–51.
Evison M, Clive A, Castle L, et al. Resectable clinical N2 non–small cell lung cancer: what is the optimal treatment strategy? An update by the British Thoracic Society Lung Cancer Specialist Advisory Group. J Thorac Oncol 2017; 12: 1434–1441.
Evison M, McDonald F, Batchelor T. What is the role of surgery in potentially resectable N2 non-small cell lung cancer? Thorax 2018; 73: 1105.
Putora PM, Leskow P, McDonald F, et al. International guidelines on stage III N2 non-small cell lung cancer: surgery or radiotherapy? ERJ Open Res 2020; 6: 00159-2019. in press.
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379: 2342–2350.
Panje CM, Glatzer M, Siren C, et al. Treatment options in oncology. JCO Clin Cancer Inform 2018; 2: 1–10.
Glatzer M, Panje CM, Siren C, et al. Decision-making criteria in oncology. Oncology 2020; 98: 370–378.
McElnay PJ, Choong A, Jordan E, et al. Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease: systematic review and meta-analysis of randomised trials. Thorax 2015; 70: 764–768.
Ankolekar A, Dekker A, Fijten R, et al. The benefits and challenges of using patient decision aids to support shared decision making in health care. JCO Clin Cancer Inform 2018; 2: 1–10.
McAlpine K, Lewis KB, Trevena LJ, et al. What is the effectiveness of patient decision aids for cancer-related decisions? A systematic review subanalysis. JCO Clin Cancer Inform 2018; 2: 1–13.
Ernst E, Pittler MH. Systematic reviews neglect safety issues. Arch Intern Med 2001; 161: 125–126.
Hopewell S, Wolfenden L, Clarke M. Reporting of adverse events in systematic reviews can be improved: survey results. J Clin Epidemiol 2008; 61: 597–602.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 4.0. Bethesda, National Cancer Institute. 2009.
Chen J, Ou L, Hollis SJ. A systematic review of the impact of routine collection of patient-reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res 2013; 13: 211.
Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377–381.
Burkes RL, Ginsberg RJ, Shepherd FA, et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto phase II trial. J Clin Oncol 1992; 10: 580–586.
Strauss GM, Herndon JE, Sherman DD, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992; 10: 1237–1244.
Giordano FA, Welzel G, Siefert V, et al. Digital follow-up and the perspective of patient-centered care in oncology: what’s the PROblem? Oncology 2020; 98: 379–385.
Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207–214.
Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176–181.
Zhang S, Liang F, Tannock I. Use and misuse of common terminology criteria for adverse events in cancer clinical trials. BMC Cancer 2016; 16: 392.
Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 2014; 106: dju244.
Pezzi CM, Mallin K, Mendez AS, et al. Ninety-day mortality after resection for lung cancer is nearly double 30-day mortality. J Thorac Cardiovasc Surg 2014; 148: 2269–2278.
Green A, Hauge J, Iachina M, et al. The mortality after surgery in primary lung cancer: results from the Danish Lung Cancer Registry. Eur J Cardiothorac Surg 2016; 49: 589–594.
Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2181–2190.
van Tol-Geerdink JJ, Stalmeier PFM, Pasker-de Jong PCM, et al. Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. Int J Radiat Oncol Biol Phys 2006; 64: 534–543.
Rauma V, Sintonen H, Räsänen JV, et al. Long-term lung cancer survivors have permanently decreased quality of life after surgery. Clin Lung Cancer 2015; 16: 40–45.
Hopkins KG, Ferson PF, Shende MR, et al. Prospective study of quality of life after lung cancer resection. Ann Transl Med 2017; 5: 204.
Ayabe T, Tomita M, Nose N, et al. Patient-reported outcomes of surgery of non-small cell lung cancer: evaluation based on the questionnaires of anti-aging quality of life and the European Organization for the Research and Treatment of Cancer quality of life questionnaire. Surg Sci 2017; 8: 203.
Bouazza YB, Chiairi I, El Kharbouchi O, et al. Patient-reported outcome measures (PROMs) in the management of lung cancer: a systematic review. Lung Cancer 2017; 113: 140–151.
Fleischmann M, Vaughan B. The challenges and opportunities of using patient reported outcome measures (PROMs) in clinical practice. Int J Osteopath Med 2018; 28: 56–61.
Weenink J-W, Braspenning J, Wensing M. Patient reported outcome measures (PROMs) in primary care: an observational pilot study of seven generic instruments. BMC Fam Pract 2014; 15: 88.
Falchook AD, Green R, Knowles ME, et al. Comparison of patient-and practitioner-reported toxic effects associated with chemoradiotherapy for head and neck cancer. JAMA Otolaryngol Head Neck Surg 2016; 142: 517–523.
Holmes MM, Lewith G, Newell D, et al. The impact of patient-reported outcome measures in clinical practice for pain: a systematic review. Qual Life Res 2017; 26: 245–257.
Ohorodnyk P, Eisenhauer EA, Booth CM. Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point? Eur J Cancer 2009; 45: 2249–2252.
Bottomley A, Pe M, Sloan J, et al. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol 2016; 17: e510–e514.
Trotti A, Colevas AD, Setser A, et al. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 2007; 25: 5121–5127.
